Angiogenesis and breast cancer;Angiogenèse et cancer du sein

Bulletin du Cancer

Volumn 94, Issue SPECIAL, 2007, Pages

  Bachelot, Thomas ^a   Ray Coquard, Isabelle ^a   Cassier, Philippe ^a   Blay, Jean Yves ^a,b  

^a CENTRE LÉON BÉRARD   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Angiogenesis; Breast cancer

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; TRASTUZUMAB; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; REVIEW;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; ENZYME INHIBITORS; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548620579     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0361     Document Type: Review

References (68)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995 ; 1 : 27-31.
2. Zhang HT, Craft P, Scott PA, Ziche M, Weich HA, Harris AL, et al. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst 1995 ; 87 : 213-9.
3. Ruohola JK, Viitanen TP, Valve EM, Seppanen JA, Loponen NT, Keskitalo JJ, et al. Enhanced invasion and tumor growth of fibroblast growth factor 8b-overexpressing MCF-7 human breast cancer cells. Cancer Res 2001 ; 61 : 4229-37.
4. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Angiogenesis 2002 ; 5 : 35-44.
5. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002 ; 62 : 4645-55.
6. Sacco MG, Cato EM, Ceruti R, Soldati S, Indraccolo S, Caniatti M, et al. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTV neu transgenic mice. Gene Ther 2001 ; 8 : 67-70.
7. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, et al. A model of human tumor dormancy : an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006 ; 98 : 316-25.
8. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997 ; 57 : 3924-8.
9. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis : novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001 ; 21 : 3995-4004.
10. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo : angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997 ; 151 : 1523-30.
11. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000 ; 60 : 3183-90.
12. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells : a complex interplay between estrogen receptors alpha and beta. Cancer Res 2002 ; 62 : 4977-84.
13. Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001 ; 61 : 6952-7.
14. Falette N, Paperin MP, Treilleux I, Gratadour AC, Peloux N, Mignotte H, et al. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res 1998 ; 58 : 1451-5.
15. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991 ; 324 : 1-8.
16. Folkman J. Tumor angiogenesis : therapeutic implications. N Engl J Med 1971 ; 285 : 1182-6.
17. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis : a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992 ; 84 : 1875-87.
18. Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994 ; 86 : 614-9.
19. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer : a systematic review of the litetature and meta-analysis. Cancer Res 2004 ; 64 : 2941-55.
20. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997 ; 57 : 963-9.
21. Brown LF, Guidi AJ, Schnitt SJ, Van De WL, Iruela-Arispe ML, Yeo TK, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999 ; 5 : 1041-56.
22. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000 ; 5 (Suppl. 1): 37-44.
23. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001 ; 61 : 5407-14.
24. Ryden L, Jirstrom K, Bendahl PO, Ferno M, Nordenskjold B, Stal O, et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor of human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005 ; 23 : 4695-704.
25. Bos R, van der GP, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003 ; 97 : 1573-81.
26. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003 ; 106 : 468-71.
27. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005 ; 65 : 5015-9.
28. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, et al. Vascular endothelial growth factor (VEGF) in breast cancer : comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000 ; 60 : 2898-905.
29. Salven P, Perhoniemi V, Tykka H, Maenpaa H, Joensuu H. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat 1999 ; 53 : 161-6.
30. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003 ; 88 : 1721-6.
31. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001 ; 19 : 1207-25.
32. Millet KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005 ; 23 : 792-9.
33. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996 ; 86 : 353-64.
34. Bachelot T, Ratel D, Menetrier-Caux C, Wion D, Blay JY, Berger F. Autoantibodies to endostatin in patients with breast cancer : correlation to endostatin levels and clinical outcome. Br J Cancer 2006 ; 94 : 1066-70.
35. Alba E, Llombart A, Ribelles N, Ramos M, Fernandez R, Mayordomo JI, et al. Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. Clin Transl Oncol 2006 ; 8 : 193-9.
36. Feldman AL, Pak H, Yang JC, Alexander HR, Libutti SK. Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer 2001 ; 91 : 1525-9.
37. Iizasa T, Chang H, Suzuki M, Otsuji M, Yokoi S, Chiyo M, et al. Overexpression of collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res 2004 ; 10 : 5361-6.
38. Schneider BP, Miller KD. Angiogenesis of breast cancer. J Clin Oncol 2005 ; 23 : 1782-90.
39. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006 ; 3 : 24-40.
40. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin : an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997 ; 88 : 277-85.
41. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy : from the research laboratory into the oncology clinic. Ann Oncol 2002 ; 13 : 12-5.
42. Edwards DR, Murphy G. Cancer proteases : invasion and more. Nature 1998 ; 394 : 527-8.
43. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002 ; 87 : 161-7.
44. Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, et al. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy : Eastern Cooperative Oncology Group trial E2196. J Clin Oncol 2004 ; 22 : 4683-90.
45. Miller KD, Gradishar W, Schuchter L, Sparano JA, Cobleigh M, Robert N, et al. A randomized phase II pilot trial of adjuvant marimastat in patients with early-stage breast cancer. Ann Oncol 2002 ; 13 : 1220-4.
46. Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Spatano JA, et al. A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res 2004 ; 10 : 1971-5.
47. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001 ; 57 : 365-76.
48. Baidas SM, Winer EP, Fleming GF, Harris L, Pluda JM, Crawford JG, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000 ; 18 : 2710-7.
49. Morabito A, Carillio G, Longo R, Gasparini G. Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer. Cancer J 2005 ; 11 : 248-51.
50. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002 ; 20 : 3792-803.
51. Eder Jr. JP, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002 ; 20 : 3772-84.
52. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer : antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002 ; 13 : 73-80.
53. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer : antitumor activity and biological effects. Ann Oncol 2006 ; 17 : 232-8.
54. Kerbel RS, Viloria-Petit A, Klement G, Rak J. "Accidental" anti-angiogenic drugs, anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000 ; 36 : 1248-57.
55. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004 ; 9 (Suppl. 1) : 2-10.
56. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006 ; 24 : 769-77.
57. Kerbel RS. A cancer therapy resistant to resistance. Nature 1997 ; 390 : 335-6.
58. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003 ; 30 : 117-24.
59. Ramaswamy S, Rhoades C, Kendra K, Hauger M, Allen J, Jhaveri S, et al. CTEP-sponsored phase II trial of bevacizumab (Avastin) in combination with docetaxel (Taxotere) in metastatic breast cancer. 26th Annual San Antonio Breast Cancer Symposium 2003 (abstr. 224).
60. Pegram M, Yeon C, Ku N, Gaudreault J, Slamon DJ. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF). 27th Annual San Antonio Breast Cancer Symposium 2004 (abstr. 3039).
61. Dickler M, Rugo HS, Caravelli J, Brogi E, Sachs D, Panageas KS, et al. Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), in patients with metastatic breast cancer. ASCO Annual Meeting 2004 (abstr. 2001).
62. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide : preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003 ; 21 : 4165-74.
63. Miller KD, Wang ML, Gralow JR, Dickler M, Cobleigh M, Perez EA, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer : a trial coordinated by the Eastern Cooperative Oncology Group (E2100). 28th Annual San Antonio Breast Cancer Symposium 2005 (abstr. 3).
64. Burstein H, Spigel D, Kindsvogel K, Parker LM, Bunnell C, Patridge A, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer : a randomized phase II study. 28th Annual San Antonio Breast Cancer Symposium 2005 (abstr. 4).
65. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005 ; 11 : 3369-76.
66. Miller KD, Burstein H, Elias A, Rugo HS, Cobleigh M, Wolff AC, et al. Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients with previously treated metastatic breast cancer (MBC). 28th Annual San Antonio Breast Cancer Symposium 2005 (abstr. 1066).
67. Rugo HS, Stopeck A, Badorf A, Pithvala Y, Steinfeldt H. A phase I/II study of AG-013736, an oral anti-angiogenesis agent, in combination with docetaxel in patients with metastatic breast cancer (MBC). 28th Annual San Antonio Breast Cancer Symposium 2005 (abstr. 1067).
68. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 ; 349 : 427-34.